Glycogen synthase kinase3 (GSK3) is an ubiquitously expressed serine threonine kinase originally characterized (and named) as an enzyme, which phosphorylated and inactivated glycogen synthase, an important mediator of glycogen biosynthesis. 1 However, GSK3 has subsequently been shown to phosphorylate a wide range of cellular proteins and to have a central role in multiple cellular functions governing cell metabolism, gene expression, cell division, apoptosis, stem cell maintenance and differentiation.
2 GSK3 includes two closely related isoforms GSK3a and GSK3b, which exhibit 97% sequence identity within their catalytic domains, but which are encoded by two separate non-functionally equivalent genes. GSK3-mediated phosphorylation has been implicated in regulating the proteolytic degradation of potential oncogenic proteins including c-myc, c-jun, cyclin D1, cyclin E and Notch1 (ref.3) suggesting that activated GSK3 acts as a tumor suppressor. In contrast, inhibiting GSK3 triggers the apoptosis of colorectal cancer cell lines, 4 and pharmacological inhibitors of GSK3 inhibit the proliferation and/or trigger the differentiation of MLL-oncogeneassociated biphenotypic leukemia.
5 Thus GSK3 appears to act as a tumor suppressor in some cell types although enhancing antiapoptotic and/or leukemogenic activity in others.
Here we describe a novel role for GSK3b in regulating retinoic acid receptor (RAR) activity as well as the proliferation and differentiation of all-trans retinoic acid (ATRA)-sensitive myeloid leukemia cells. We initially assessed the relative activity of GSK3 during the ATRA-mediated granulocytic differentiation of the NB4 promyelocytic leukemia cell line. The enzymatic activity of GSK3b is markedly inhibited by phosphorylation of an N-terminal serine residue (Ser 9 ) and this phosphorylation can be detected with a GSK3b (S9) phospho-specific antibody (Cell Signaling Technology, Danvers, MA, USA). We observe that ATRA induces this inhibitory phosphorylation of GSK3b in NB4 cells. This enhanced phosphorylation occurs rapidly (within 1 h) following ATRA exposure and progressively increasesFpeaking at 3-5 days following differentiation induction (Figure 1a ). This ATRAinduced GSK3b N-terminal phosphorylation occurs in a dosedependent manner (Figure 1b) . In contrast the level of total GSK3b remains constant during this ATRA-induced leukemia cell differentiation (Figures 1a and b) . A similar enhanced phosphorylation of GSK3b Ser 9 occurs in the ATRA-responsive HL60 cell line (Figure 1c) but not in the ATRA-resistant K562 cell line (Figure 1d) .
The above observations indicate that the ATRA-induced granulocytic differentiation of myeloid leukemia cells is associated with inhibition of GSK3b activity. To determine whether this reduced GSK3b activity might be involved in regulating this differentiation, we incubated the ATRA-responsive NB4 cells with various small molecule inhibitors of GSK3b. Surprisingly we observed that virtually all of these GSK3 chemical inhibitors as single agents induced morphologic granulocytic differentiation of the NB4 cells to a degree comparable to that induced by ATRA ( Figure 2a ). As with ATRA-induced differentiation this morphologic differentiation induced by GSK3 inhibitors is accompanied by enhanced expression of the neutrophil surface antigen CD11b, a widely used marker of granulocytic differentiation (Figure 2b ), as well as by growth arrest of the differentiating cells (Figure 2c ). Furthermore, gene products that are known to be upregulated during ATRA-induced myeloid leukemia cell differentiation such as Id1, C/EBPe, Stat1, p21 and p27 are also upregulated by these GSK3 inhibitors (Figure 2d ). Moreover, GSK3 inhibition also reduced CDK8 and c-Myc gene expression as well as the activated (phosphorylated) CaMKIIg (Figure 2d ), which acts as a negative regulator of myeloid leukemia differentiation. Letters to the Editor inhibitors in myeloid leukemia cell differentiation, we treated NB4 cells using a combination of both drugs at concentrations that exhibit only a minimal effect on differentiation as single agents. We observed that the drug combination significantly induced morphologic granulocytic differentiation of NB4 cells with concurrent enhanced Cd11b expression (Figure 2e ).
Our observations that GSK3 pharmacological inhibitors trigger the differentiation of ATRA-sensitive myeloid leukemia cell lines and also synergistically enhance ATRA-induced differentiation suggest that GSK3 may be directly involved in RAR activity. Therefore we assessed the effect of GSK3b on RAR transcriptional activity. We observe in NB4 cells that the ATRAinduced activity of the ATRA-responsive luciferase reporter harboring a retinoic acid response element (RARE) is markedly diminished when co-transfected with a GSK3b expression vector ( Figure 3a ). This inhibition of RAR transcriptional activity is dependent upon the kinase activity of GSK3b as a 'kinasedead' GSK3b construct harboring a point mutation within the ATP-binding site of GSK3b (K85R) did not exhibit any inhibition of RAR activity in the same assay ( Figure 3a) . We also observed that the activity of this same RARE luciferase reporter was enhanced by the GSK3 pharmacological inhibitor, BIO Letters to the Editor compare lanes 2-4 with lanes 6-8). Thus the kinase active GSK3b downregulates RAR transcriptional activity and pharmacological inhibition of GSK3b enhances RAR activity.
To determine whether RARa may be an enzymatic substrate of GSK3b, we performed in vitro kinase reactions and observed that GSK3b can directly phosphorylate RARa and that this phosphorylation was inhibited by pharmacological inhibitors (BIO and SB212763) of GSK3b (Figure 3c ). This phosphorylation occurs at the N-terminus of RARa as GSKb readily phosphorylates a Gst-RARa fusion protein harboring only aa 1-86 of RARa but does not phosphorylate a Gst-RARa fusion protein lacking this RARa N-terminus (Figure 3d , compare lanes 7 and 8). We observed two consensus GSK3b phosphorylation sites (Ser/Thr-X-X-X-Ser/Thr) 2 within the N-terminus of RARa at aa51-55 and at aa63-67 (Figure 3e ). Mutating these sites (S51A, T55A, T63A and S67A) markedly inhibited the in vitro GSK3b-mediated phosphorylation of RARa (Figure 3f ). Thus RARa is directly phosphorylated by GSK3b at specific N-terminus sites. To determine whether this phosphorylation had any functional significance, we compared the transcriptional activity of a wildtype RARa with RARa constructs mutated at these GSK3b phosphorylation sites. RARa expression vectors harboring mutations at each of these four sites stimulated RARE-luciferase reporter activity to a significantly greater degree than the wild-type RARa expression vector (Figure 3g ). This indicates that the GSK3b-mediated phosphorylation of RARa at specific N-terminus sites is associated with an inhibition of RARa transcriptional activity.
At least 40 different substrates of GSK3 have been identified to date and our present observations indicate that the retinoic acid receptor (RARa) is an additional substrate of this enzyme. The observed N-terminal phosphorylation of RARa by GSK3 inhibits RARa activity, and this appears to be biologically significant as pharmacological inhibitors of GSK3 enhance RARa activity (Figure 3b ) and induce the differentiation of ATRA-sensitive myeloid leukemia cells (Figure 2 ). We do not know precisely how this N-terminal phosphorylation of RARa by GSK3b results in this inhibition of RARa activity. The phosphorylation of certain substrates by GSK3 enhances their proteolytic degradation 3 and it is possible that the GSK3-mediated phosphorylation of RARa similarly enhances its degradation. Consistent with this possibility we observe that the expression of RARa is enhanced by GSK3 pharmacological inhibitors in ATRA-sensitive leukemia cells (Figure 4a ). Interestingly we have also observed that treatment of myeloid leukemia cells with GSK3 inhibitors triggers enhanced expression of a number of RAR transcriptional co-activators including p300, CBP and SRC-1 (Figure 4b ). Indeed the GSK3/RARa interaction we have observed may merely represent the 'tip of the iceberg' and multiple other members of the RAR transcriptional complex may also be phosphorylated/regulated by GSK3. Thus the effect of GSK3 inhibitors in enhancing RAR transcriptional activity and triggering myeloid cell differentiation may involve not only their triggering enhanced RARa expression but also their inducing the enhanced expression/activity of associated RARa transcriptional co-activators.
Irrespective of defining the exact mechanism of action of GSK3 in inhibiting RAR transcriptional activity, it is clear from our experimental observations that pharmacological inhibitors of GSK3 as single agents are potent inducers of the terminal differentiation of ATRA-sensitive myeloid leukemia cell lines. There has been considerable interest in the pharmaceutical industry to identify and characterize small molecule inhibitors of GSK3 given the potential role of such inhibitors in overcoming insulin resistance and treating diabetes mellitus. 7 Moreover, GSK3 has been implicated in enhancing b-amyloid deposits in the brain and certain GSK3 pharmacological inhibitors have entered clinical phases of development to determine their safety and efficacy in the treatment of Alzheimer's disease. 8 Our present experimental observations together with the previous observations in MLL-associated leukemias 5 suggest that such specific GSK3 inhibitors may also prove beneficial in the treatment of certain human myeloid leukemias either by themselves or in combination with other therapeutic agents. Letters to the Editor The Wilms' tumor 1 (WT1) gene, located at chromosome band 11p13, encodes a transcriptional regulator with an N-terminal domain (exons 1-6) and a C-terminal domain containing four zinc-finger motifs (exons 7-10). Among the targets of WT1 are many genes involved in apoptosis, cell cycle and proliferation.
Originally named for its role in Wilms' tumor, a pediatric kidney malignancy, WT1 has since been found to be implicated in several hematological malignancies, particularly in acute myeloid leukemia (AML). The role of WT1 in AML has been underlined by the finding of WT1 overexpression in 80-90% of AML and WT1 mutations in B10% of AML, but its contribution to leukemogenesis has still not been clarified. 1 Special attention has been paid to the synonymous (Arg301) single-nucleotide polymorphism (SNP) rs16754 of WT1 (903A4G), due to its location in exon 7, a mutational hotspot of WT1 gene in acute leukemia. Recently, WT1 SNP rs16754 was suggested to predict favorable clinical outcome in adults with cytogenetically normal (CN) AML. 2 Conflicting data on the prognostic impact of this SNP have subsequently been reported in pediatric AML.
3,4 In our study, we assessed the prevalence, the main associated features and the prognostic significance of WT1 SNP rs16754 in a large cohort of adult AML patients.
This study was performed in patients with previously untreated de novo AML (M3-AML excluded) and enrolled on the prospective French ALFA-9801 or ALFA-9802 trials. Details of the treatment protocols have been previously described. 5, 6 These studies were approved by the ethic committees of SaintLouis Hospital (ALFA-9801: number 9959) and Lyon B-Hotel Dieu Hospital (ALFA-9802: number 99017B). Informed consent was obtained from all patients in accordance with the Declaration of Helsinki. Overall, 937 patients were included in these trials. This retrospective screening involved 511 patients for whom frozen material collected at time of AML diagnosis was available for molecular analysis. This selected cohort did not significantly differ from the whole cohort in terms of patient characteristics and clinical outcome (data not shown). Genomic DNA was extracted from pre-treatment bone marrow or peripheral blood samples using standard procedures. WT1 exons 7 (including SNP rs16754) and 9 were amplified by PCR, and purified PCR fragments were directly sequenced in both directions, as described elsewhere.
7 Mutations of NPM1, CEBPA, IDH1 and IDH2 exon 4, and FLT3 internal tandem duplication (FLT3-ITD) were investigated as previously reported. 8 Patient characteristics and complete remission rates comparisons were performed using the Fisher exact test for binary variables and the Mann-Whitney test for continuous variables. Overall survival and relapse risk were estimated by the Kaplan-Meier method. For overall survival, patients were censored at last follow-up if alive or at the time of allogeneic transplantation. All survival analyses were performed using a Cox model regression and adjusted on protocol (ALFA-9801 vs ALFA-9802) as covariate. A P-value p0.05 was considered to indicate statistical significance.
The minor allele of WT1 SNP rs16754 was found in 141/511 (27.6%) patients, at the heterozygous state (WT1 AG ) in 123 (24%) and homozygous state (WT1 GG ) in 18 (3.6%). These frequencies are similar to those previously observed in AML patients and in controls. [2] [3] [4] Comparisons of clinical and biological characteristics of patients were performed according to WT1 SNP rs16754 status. In our cohort, patients with at least one minor allele were found to be older than patients with two major alleles (median age: 54 vs 49 years, P ¼ 0.006). As WT1 SNP rs16754 is a germline genetic variation, its frequency is not expected to change with age. Consequently, our finding is very likely to reflect a sampling bias. Patients were not equally distributed across the French-American-British subtypes, with a higher prevalence of M5-AML in patients with at least one minor allele (23% vs 14%, P ¼ 0.02). No other association between WT1 SNP rs16754 status and pre-treatment patient characteristics was found (Table 1 ). In particular, we did not observe any association between the presence of a WT1 mutation and WT1 SNP rs16754 status, in accordance with two previous studies.
2,4 Strikingly, Ho et al. 3 reported that WT1 mutations rarely occur in patients with one minor allele of WT1 SNP rs16754 and are even absent in patients homozygous for the minor allele, suggesting for the first time a link between the acquisition of a WT1 mutation and the SNP rs16754 status.
In univariate analysis, patients with at least one minor allele and patients with two major alleles showed no difference in complete remission rates (82% vs 83%, P ¼ 0.93), 5-year relapse risk (62% vs 67%, P ¼ 0.55) (Figure 1a) and 5-year overall survival (32% vs 37%, P ¼ 0.11) (Figure 1b) . Likewise, within the subset of CN-AML (n ¼ 208), WT1 SNP rs16754 status had no influence on response to induction chemotherapy (complete remission rates 84% vs 83%, P ¼ 0.99) and no significant impact on a 5-year relapse risk (69% vs 64%, P ¼ 0.08; Figure 1c) and 5-year overall survival (35% vs 40%, P ¼ 0.38; Figure 1d ). As WT1 SNP rs16754 status was significantly associated with age, we also performed a survival analysis after adjustment on age as continuous covariate, which confirmed the absence of impact of this SNP on patient outcome.
Thus, in our whole cohort of adult AML patients, WT1 SNP rs16754 status did not correlate with clinical outcome, in agreement with Hollink et al. 4 who found no prognostic impact of this SNP in pediatric AML. In contrast, two studies, one performed in adult CN-AML and the other in pediatric AML, reported that the minor allele of WT1 SNP rs16754 predicts significantly improved clinical outcome.
2,3 However, the
